Product & Industry News
Drug Discovery World
Symbiosis secures £1 million of growth finance from Allied Irish Bank

Symbiosis secures £1 million of growth finance from Allied Irish Bank

1 July 2020
Image: Micheile Henderson

Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy.

Symbiosis provides niche, sterile manufacturing services to global biotechnology and pharmaceutical company clients that are developing novel drug therapies and vaccines for use in clinical trials or the commercial market.

Symbiosis’s facility at Stirling Innovation Park was purpose built in 2011 to manufacture deliberately small batches of clinical trial injectable drug products.

Since then, the company has grown significantly and has positioned itself to supply commercial pharmaceutical products and specialise in emerging medicinal technologies like Advanced Therapeutic Medicinal Products (ATMPs).

Allied Irish Bank (GB) will provide £1million of debt funding to enable physical, operational and commercial development of the business, including enhanced manufacturing output, improved business process efficiency and a strengthened IT capability.

The financing will also support Symbiosis’s plan to hire 20 more staff by the end of 2020 and continue its trend of annual, double-digit revenue and profit increases.

The Allied Irish Bank (GB) finance package follows a recent period of expansion by Symbiosis, part-funded by Innovate UK grant funding.

Last year the firm completed the investment of £1.5 million in its Stirling headquarters, doubling its footprint and increasing its manufacturing capability.

Tina Crookston, relationship manager at Allied Irish Bank (GB), said: “Symbiosis has consistently exceeded its business goals and has strong potential for growth.

“Life sciences is a billion-pound sector in Scotland and homegrown startups like Symbiosis are a critical part of that success.”

Colin MacKay, CEO of Symbiosis said: “The funding from Allied Irish Bank (GB) is a significant statement of support and endorses our growth strategy. We will be using that investment to proactively fuel the strategic development of our capabilities to enable further successful growth in both local and international markets. We want to increase our manufacturing output while maintaining the time-focused competitive strengths that our market has come to expect."

More on this subject...
Drug Discovery World

Symbiosis to manufacture COVID-19 vaccine for clinical trials READ MORE

Drug Discovery World

Sanofi and Regeneron stop Kevzara COVID-19 trial in US READ MORE

Drug Discovery World

Avacta and Daewoong Pharmaceutical partnership to include COVID-19 neutralising Affimer therapy READ MORE